• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio

    Frontage Bolsters Clinical Services Capabilities

    Sanofi Unveils EUROAPI as Name of New European API Company

    Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz

    Precision Medicine Group Acquires Project Farma
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Sanofi Unveils EUROAPI as Name of New European API Company

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza

    Fujifilm, CABIM Get $76M Funding for Mfg. and Innovation Center

    LSNE Expands Fill Finish and Lyophilization Ops
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe

    Schreiner MediPharm Joins DoseID Consortium
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Virtual Clinical Trials: The Future of Dermatology Studies

    Frontage Bolsters Clinical Services Capabilities

    Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    CDMO Cognate BioServices Teams Up with L7 Informatics

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    The Wasdell Group Earns ISO 13485 Certification
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Adare Pharma Solutions

    Cytovance Biologics

    Syngene

    Alcami
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    PCI Pharma Services

    Cytovance Biologics

    Flow Sciences

    Baxter BioPharma Solutions

    Emergent BioSolutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Globalization Hits Biopharma Contract Manufacturing

    CMOs no longer need to be local, and some countries are set to benefit

    Related CONTENT
    • Cytiva Delivers Modular Biologics Factory to Lonza
    • Fujifilm, CABIM Get $76M Funding for Mfg. and Innovation Center
    • Capricor, Lonza Enter CAP-1002 Development Agreement
    • Oligonucleotides
    • Genezen Laboratories Receives Growth Equity Investment
    Eric S. Langer, BioPlan Associates10.07.15
    Being located next door to one’s contract service provider used to be a practical necessity. But over the past 10 years that’s changed, and today virtually no biopharmaceutical manufacturing client considers the geographic proximity of their contract manufacturing organization (CMO) to be a very important factor in their selection process. Specifically, less than 2% of clients surveyed for BioPlan Associates’ 12th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production cited this as a critical factor, down from double-digit percentages a decade ago. Indeed, of the 19 selection criteria that we’ve measured over the past decade, a CMO’s proximity has seen the second-largest negative swing in importance. 

    Take that in combination with the greater degree of outsourcing that we’ve witnessed over the years, and the implications are clear: CMOs all over the world are more in competition than ever to win same lucrative contracts. Certainly, companies may well prefer to do business with CMOs that are in the same country or region (locality, after all, means different things to different people), for the cultural comfort of doing so if nothing else. But as this industry has matured, biomanufacturing has undergone the same transformations as generally seen in the world economy: More clients have the experience and sophistication to manage their offshore suppliers. In addition, some clients view their CMOs international regulatory expertise as supporting international marketing opportunities.

    As the industry becomes increasingly global, it’s intriguing to see how the rankings of favored offshoring countries evolve over time. These rankings may be influenced by experiences, press reports, specific CMOs or other factors, but they nonetheless offer an overarching indication of how well certain countries are expected to fare in drawing foreign contracts.

    Top Destinations for International Outsourcing
    This year traditional powerhouses reign again in the overall rankings of possible destinations. When we asked qualified industry respondents to identify where they would consider outsourcing production outside of their own country over the next five years, we found that the US and Germany tied at the top of the list, each cited by more than one-quarter (26.5%) of the industry. For Germany this caps a strong increase from 16% citing the prior 2 years, while for the US it marks another year at the top. The US has a strong reputation as a global biomanufacturing hub, accounting more than one-third of global biomanufacturing facility capacity, according to our analyses of the top facilities worldwide.

    Behind the US and Germany but well atop the list of BRIC countries was China, indicated to be a possible destination by 22% of industry respondents, a figure that puts it slightly behind last year’s tally of 24% but still up from 10.6% the year before. (Brazil and India, meanwhile, were fairly tightly bunched at around 10% of respondents). Following China was the UK (17.6%) and then Singapore and Switzerland.

    Possible Destination? Differences Abound Across the Atlantic
    Our study includes a global sample from 28 countries, and while the geographic distribution has remained relatively steady over the years, that distribution can affect the overall rankings, given that this specifically measures off-shoring destinations.
    As a result, we also break out our respondents by respondent region, honing in on US-based and Western European companies. It was in these breakouts that we saw some of the larger swings in country perceptions this year.

    Among US-based client companies, for example, fully half cited Germany as a possible international outsourcing destination. That marks a substantial uptick from 36% last year, but continues a trend that has seen an increase each year since 2011, when fewer than one-quarter (22%) saw Germany as a potential destination. Germany’s popularity is most likely fueled by the presence of world-class CMOs and facilities. For example, two German facilities—Boehringer Ingeleheim’s Biberach biomanufacturing facility and Hoffmann-La Roche’s Penzberg biomanufacturing facility—rank among the top 10 worldwide facilities on our Wiki site (top1000bio.com), which ranks the top 1000 biomanufacturing facilities worldwide using a proprietary weighted scale. No other country besides the US and Germany place a facility in our top 10.

    Last year’s top potential destination among US-based client companies, Singapore, was cited again by 38.6% of respondents, good for the second position. It was ahead of China (34.1%, up from 25%), Ireland (29.5%, up from 27.3%) and the UK (27.3%, up from 22.7%).

    Among respondents based in Western Europe there was no such consensus. A group of countries—the US, China, Germany, the UK, Brazil and Austria—all carried equal weight among respondents as possible destinations, a surprising result to be sure. What the multi-year trend does show, however, is a growing preference for both Germany and the UK. European companies, it seems, are happy enough to offshore within the same region.

    To get a better sense of how these perceptions might materialize into future business, we also asked respondents from both regions to identify the countries where there was a “strong likelihood” or a “likelihood” that they would outsource production over the next 5 years. In essence, we’re looking at more positive indications of outsourcing activity than merely consideration.

    Under this scale, the UK and the US both performed well. Each was indicated as a likely destination by more than one-third of European respondents (36.4%), and each appears to be growing in favor over previous years. This again indicates that emerging markets take a backseat to traditional hubs among Europeans. Indeed, there was less positivity to outsourcing to countries like China and Russia, and India and Brazil did not even register.

    When we ran the same test of likelihood by US-based companies, we saw that Asian markets hold considerable appeal. China (25%), Singapore (18.1%), and Korea (15.9%) all placed in the top 5 destinations. India (11.3%) also wasn’t far behind, though its appeal as an outsourcing destination seems to have waned in recent years.

    Germany again led the rankings among US companies, though, with 27.3% indicating at least a likelihood that they would outsource production there in the next 5 years. This represents the highest level of positive interest in Germany in at least 7 years, up from a previous high of 19.4% in 2013. The country may be boosted by not only housing a large CMO such as Boehringer Ingelheim, which has achieved licensing for manufacture of marketed biologics, but also mid-tier CMOs such as Rentschler, which has recently been expanding. Smaller-scale European CMOs also tend to be clustered in these regions, as well as in Switzerland and the Netherlands.

    The greatest percentage of European client companies (36.4%) targeted the UK as their preference as a Likelihood, or Strong Likelihood outsourced capacity destination, Following were the US, Austria, and the Netherlands.  That Germany fell low on this list may be due to the relatively large percentage of European respondents coming from that country. 

    Process Development Offshoring Projections Lose Steam
    It’s important to note that while off-shoring may be more common now than it was, industry attitudes take divergent paths when we measure different types of activities in consideration for outsourcing.

    For example, among all respondents, the enthusiasm for offshoring is greatest for clinical trials and operations, as 58% of respondents see this as being in their future to some degree over the next 5 years. This number has been steady over the past couple of years but has grown substantially from earlier this decade.

    By comparison, fewer industry respondents—43.2% in sum—expect to offshore at least some of their biomanufacturing operations over the next 5 years. That figure is down slightly from last year’s 47%, but still exhibits an overall growth trend since 2011.

    In contrast to those examples, though, stands process development (PD). Over the years, we’ve witnessed a gradual decline in the proportion of industry respondents who expect to offshore process development operations. This appears to increasingly seen as a core operation, important to the business interests of biomanufacturers. Now, just over 3 in 10 (30.9%) predict that they will outsource PD over the next 5 years, down significantly from 2012 where 46.4% planned on outsourcing PD.  This is surprising in light of the fact that these same decision makers plan to increase their PD budgets by 5.3% on average this year; second only to the estimated increase in new capital equipment spending (6.3%). 

    Outsourcing vs Offshoring Process Development
    This increase in budgets, and decrease in off-shoring of high-value activities like PD, suggests that these activities are either being kept in-house, with companies preferring to increase their spending to meet their needs, or that they are considering outsourcing them domestically. In this case, enthusiasm for outsourcing process development may still exist, but not necessarily for offshoring it.
    Here’s the distinction. Our study shows that when it comes to hiring challenges, no position comes close to pains that facilities are experiencing when hiring process development staff. When we surveyed the industry on the job positions their facilities are currently finding difficult to fill, upstream and downstream process development staff emerged as the top responses by a wide margin (39% and 37%, respectively). Well ahead of quality assurance and process engineers, for example. Faced with this backdrop, we also observed a jump this year in the percentage of respondents who claimed to have outsourced jobs in process development in order to cut costs, growing to 17.3% from around 12% during the previous 4 years. So more companies are outsourcing process development jobs, presumably at least partly due to hiring difficulties (and associated cost savings from outsourcing).

    More companies are also outsourcing process development operations. In our study’s chapter on outsourcing, the data reveal that 43.2% of respondents are outsourcing at least some upstream process development, more than double the proportion doing so in 2010 (17.1%). Likewise, 41.1% reported outsourcing downstream process development, representing almost twice the share from 2010 (22.1%). And when we asked the industry what they wanted their suppliers to focus their development efforts on most, upstream and downstream process development services were the most frequently cited service areas.

    What may be occurring is a more gradual evolution in outsourcing of this particular activity, which remains among the lesser-outsourced ones of the many we test. As such, more companies may be starting to outsource process development, but not display as much comfort in offshoring these sensitive operations. And while an apparent shortage of skilled process development staff may soon cause biomanufacturers to look overseas, for now this shortage may be pushing them to value these activities even more highly and therefore consider them too much of a core activity to outsource internationally.

    Conclusion
    While process development activities may be staying close to home for now, it appears that offshoring of many aspects of biopharmaceuticals, including biomanufacturing, continue to expand, in part, due to cost factors. In fact, nearly 15% of biomanufacturers this year reported having outsourced manufacturing to non-domestic service providers specifically to reduce costs. Following the general trend, this was the 4th consecutive year of growth on this measure.

    For now, it appears that Western European companies are most comfortable offshoring to the US or countries within their own region, where numerous experienced CMOs are located. But the race for contracts appears to be far less lopsided, and while Germany is ahead for the time being, countries in the Asia-Pacific region are well and truly in the mix.


    Eric S. Langer
    BioPlan Associates

    Eric S. Langer is president and managing partner at BioPlan Associates, Inc., a biotechnology and life sciences marketing research and publishing firm established in Rockville, MD in 1989. He is editor of numerous studies, including “Biopharmaceutical Technology in China,” “Advances in Large-scale Biopharmaceutical Manufacturing”, and many other industry reports.  elanger@bioplanassociates.com; 301-921-5979;  www.bioplanassociates.com

    References
    1. 12th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, BioPlan Associates, Inc. Rockville, MD., April 2015.
    2. BioPlanAssociates,Top1000Global Biopharmaceutical Facilities Index, www. top1000bio.com, accessed July 29, 2015.
    Related Searches
    • CMO
    • Biopharma
    • International Outsourcing
    • Clinical Trials
    Suggested For You
    Cytiva Delivers Modular Biologics Factory to Lonza Cytiva Delivers Modular Biologics Factory to Lonza
    Fujifilm, CABIM Get $76M Funding for Mfg. and Innovation Center Fujifilm, CABIM Get $76M Funding for Mfg. and Innovation Center
    Capricor, Lonza Enter CAP-1002 Development Agreement Capricor, Lonza Enter CAP-1002 Development Agreement
    Oligonucleotides Oligonucleotides
    Genezen Laboratories Receives Growth Equity Investment Genezen Laboratories Receives Growth Equity Investment
    Fujifilm to Invest $40M in New Facility Fujifilm to Invest $40M in New Facility
    Lonza Expands Conjugation Facility in Visp Lonza Expands Conjugation Facility in Visp
    Passage Bio Invests in Gene Therapy Manufacturing R&D Site Passage Bio Invests in Gene Therapy Manufacturing R&D Site
    CHA Biotech Launches Global CDMO Biz CHA Biotech Launches Global CDMO Biz
    CPI Scales Up Manufacturing of Pyocin S5 CPI Scales Up Manufacturing of Pyocin S5
    Orgenesis, Cure Therapeutics Form JV Orgenesis, Cure Therapeutics Form JV
    atbtherapeutics, iBio CDMO Enter Manufacturing Agreement atbtherapeutics, iBio CDMO Enter Manufacturing Agreement
    Piramal Invests $32M to Expand Michigan Facility Piramal Invests $32M to Expand Michigan Facility
    Tubulis, WuXi Biologics and WuXi STA Form Strategic Pact Tubulis, WuXi Biologics and WuXi STA Form Strategic Pact
    iBio to Provide CDMO Services for ATB Therapeutics iBio to Provide CDMO Services for ATB Therapeutics

    Related Columns

    • Clinical Trials | Serialization | Supply Chain
      Anti-Counterfeiting in the Pharmaceutical Industry: An Evolution

      Anti-Counterfeiting in the Pharmaceutical Industry: An Evolution

      Keeping up with counterfeitors in the pharmaceutical industry is no easy task, but patients’ lives depend on it.
      Ben Locwin, Healthcare Science Advisors 10.04.19

    • Clinical Trials
      Synthetic Control Arms

      Synthetic Control Arms

      In clinical trials, they don’t always capture the most important dimensions
      Ben Locwin 03.06.19

    • Clinical Trials | Process Development

      China Vaults to the Top of U.S. Biomanufacturers’ Off-Shoring Prospects

      A look at top destinations for future offshoring
      Eric S. Langer, BioPlan Associates 06.02.16


    • Clinical Trials

      Are More CRO Transactions Near?

      When will we see additional transactions involving the largest CROs?
      Chad Moore, Leerink Partners LLC 06.02.16

    • Biosimilars | Clinical Trials | Drug Discovery | Process Development

      Like the Temperature, It Feels Like Deal Activity is Heating Up

      A summary of 2016 transactions so far
      Chad Moore, Leerink Partners LLC 05.05.16

    • Analytical Services | Clinical Trials | Laboratory Testing | Supply Chain

      Analytical Instruments are On-Board with Outsourcing

      Newer process instruments are finally being designed with mobility in mind
      Emil W. Ciurczak, DoraMaxx Consulting 01.28.16


    • Biosimilars | Clinical Trials

      Outsourced Pharma Services: 2015 Review & 2016 Outlook

      ...
      Chad Moore, Leerink Partners 01.28.16

    • APIs | Biosimilars | Clinical Trials | Process Development | Vials

      2015 in Review: 6 Key Trends Affecting CMOs

      A look at major CMO trends ranging from budgets to growth opportunities
      Eric S. Langer, BioPlan Associates 11.17.15

    • Clinical Trials | Drug Development

      Recap of Notable Recent CRO Transactions

      Conditions are expected to remain favorable for M&A and capital markets activity in the pharmaceutical service and IT sector
      Chad Moore 10.07.15


    • Clinical Trials

      Clinical Trial Participants: Why So Elusive?

      Looking at how some companies are improving clinical trial efficiency and speed to solve the clinical trial participant conundrum
      Chad Moore, Robert W. Baird & Co. Inc. 09.11.15

    • Clinical Trials | Drug Development

      Medical Affairs: The Next Wave of Outsourcing?

      Outsourcing of medical affairs is on the rise, creating opportunities for third-party providers
      Chad Moore, Robert W. Baird & Co. Inc. 07.14.15

    • Analytical Services | APIs | Bioanalytical Services | Biosimilars | Chemistry | Clinical Trials | Excipients | GMPs/GCPs | Laboratory Testing | Microbiology | QA/QC | R&D | Regulatory Affairs | Supply Chain | Toxicology | Validation

      Inventas vitam iuvat excoluisse per artes (Let us improve life through science and art)

      But Qui bono? (Who benefits?)
      Emil W. Ciurczak, DoraMaxx Consulting 07.14.15


    • Clinical Trials

      Why Do Americans Pay More for Cancer Treatments?

      The ever-increasing cost of cancer treatments globally is a constant cause for discussion and price negotiation between Pharma companies and health care providers
      Adele Graham-King, Contributing Editor 05.06.15

    • Clinical Trials | Drug Development

      M&A Activity Heats Up

      Last year was hot, but 2015 looks to be hotter.
      Chad Moore, Robert W. Baird & Co. Inc. 01.29.15

    • Capsules | Cleaning Validation | Clinical Trials | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Lyophilization | Process Development | R&D | Serialization | Supply Chain | Validation

      Sometimes, Even a Good Workman Can Blame His Tools

      A new generation of equipment will help generate products with less cost and effort, while being made more efficiently.
      Emil W. Ciurczak, DoraMaxx Consulting 01.29.15

    Trending
    • Fujifilm To Invest $2B In US Manufacturing Site
    • Baxter, Novavax Ink Sterile Manufacturing Agreement
    • A New Era Of Vaccine And Biologic Drug Development
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • Roche Canada To Invest $500M To Create 500 Jobs In Ontario
    Breaking News
    • KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio
    • Frontage Bolsters Clinical Services Capabilities
    • Sanofi Unveils EUROAPI as Name of New European API Company
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • Precision Medicine Group Acquires Project Farma
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Brown Fat Associated with Reductions in Chronic Disease Risk
    NIH Study Identifies Antibacterial Properties in Taurine
    NSF Begins New Certification Program
    Coatings World

    Latest Breaking News From Coatings World

    Zeppelin Acquires MTI Mischtechnik
    Ezio Braggio Joins ChemQuest Europe
    IFS Coatings Announce Carbon Offset Program
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Optimize EP Launches CaRM Cardiac Device Data Management Platform
    U.S. TAVR Market Projected to Reach Nearly $5 Billion by 2030
    FDA Clears Canon Medical's Compressed SPEEDER for 3D Exams on 1.5T MR
    Contract Pharma

    Latest Breaking News From Contract Pharma

    KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio
    Frontage Bolsters Clinical Services Capabilities
    Sanofi Unveils EUROAPI as Name of New European API Company
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Neenah to Host Packaging Webinar for Printers
    W.S. Badger is Named a ‘150 Top Impact Company’
    Mana Products, Meiyume and RPG Form The Vertical Beauty Alliance
    Happi

    Latest Breaking News From Happi

    A Surge in Interest for Supplements & Vitamins
    What You're Reading on Happi.com
    Three Form Vertical Beauty Alliance
    Ink World

    Latest Breaking News From Ink World

    dar-tech, inc. Becomes U.S. Midwestern Distributor for ZS Interpolymer
    Techkon USA, Konica Minolta Partner
    Alon Bar-Shany Appointed Chairman of Highcon Board
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Exhibitor registration opens for virtual.drupa
    FTA planning in-person Forum & INFOFLEX
    Fortis Solutions Group achieves SGP certification
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Shemesh Adds U.S. Headquarters
    TZMO USA, Special Needs Group Form Partnership
    BAHP Announces 2021 Officers, Board of Directors
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Rapid Recovery Protocol Can Lead to Increased Range of Motion After TKA
    Boston Scientific Releases WaveWriter Alpha Spinal Cord Stimulators in U.S.
    New Chief Clinical Officer on Board at IncludeHealth
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Toppan Announces 2050 Environmental Vision
    SOI Industry Consortium Joins SEMI as Strategic Association Partner

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login